Ruxolitinib therapy to treat corticosteroid-refractory acute and chronic graft-versus-host disease (GVHD) in transplant recipients can achieve response rates >80%, according to a multi-center study of 95 patients treated with this JAK1/2 inhibitor. In this retrospective study, 54 patients had grades III or IV acute GVHD and 41 patients had moderate or severe chronic GVHD. In each group, the median number of previous therapies to treat GVHD was 3. The overall response rate was 81.5% in acute GVHD patients, including 25 complete responses (46.3%). In chronic GVHD patients, the overall response rate was 85.4%. In patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% and 5.7% for acute GVHD and chronic GVHD, respectively.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Ruxolitinib Effective in Treating Steroid-Refractory GVHD
Sep 2015